EryDel
EryDel S.p.A. specializes in the development of drugs and diagnostics delivered through human red blood cells via a proprietary medical device technology.
Based in Milan, EryDel develops an innovative red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient’s own blood which are then re-infused into the patient. The company is led by Luca Benatti, CEO, a serial entrepreneur who previously co-founded Newron Pharmaceuticals (NWRN). EryDel’s lead product, EryDex, has received Orphan Drug designation both from the FDA and the EMA for the treatment of Ataxia Telangiectasia (AT), a rare autosomal recessive disorder for which there is currently no established therapy.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Active
Website
www.erydel.com
Related Articles
EryDel Announces Completion of Patient Enrollment in Phase 3 ATTeST Trial the Largest Clinical Study Ever Conducted in Ataxia Telangiectasia (AT)
EryDel Appoints Stan Musial as Chief Financial Officer
EryDel Appoints Ronan W. Gannon as Chief Commercial Officer
Sofinnova Partners leads EryDel’s €26.5 million financing
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.